MDT-AP-2405
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 9
- os_event
- false
- age_years
- 2
- new_clusters
- C1
- umap1_2d
- 4.629126678
- umap2_2d
- 0.065785578
- umap1_3d
- 0.35076745
- umap2_3d
- -2.773758847
- umap3_3d
- 0.080185517
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.430
- INFLAMMATORY_RESPONSE+0.400
- IL6_JAK_STAT3_SIGNALING+0.370
- ANGIOGENESIS+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
- KRAS_SIGNALING_UP+0.350
- INTERFERON_ALPHA_RESPONSE+0.330
- ALLOGRAFT_REJECTION+0.320
- TGF_BETA_SIGNALING+0.320
- INTERFERON_GAMMA_RESPONSE+0.310
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- E2F_TARGETS-0.520
- G2M_CHECKPOINT-0.460
- HEDGEHOG_SIGNALING-0.400
- MITOTIC_SPINDLE-0.370
- MYC_TARGETS_V1-0.340
- UNFOLDED_PROTEIN_RESPONSE-0.210
- DNA_REPAIR-0.200
- GLYCOLYSIS-0.140
- SPERMATOGENESIS-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088905 | — | — | 0.896 |
| 2 | SRR5088904 | — | — | 0.894 |
| 3 | SAMN03290935 | — | — | 0.892 |
| 4 | SRR22247245 | — | cohortMD2 | 0.885 |
| 5 | MDT-AP-0484 | Med | Medulloblastoma | 0.884 |
| 6 | BS_E4F1D721 | Spinal Cord Ependymoma | — | 0.881 |
| 7 | SRR5088928 | — | — | 0.879 |
| 8 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.878 |
| 9 | BS_E4F1D721 | EPN | EPN Tumor | 0.874 |
| 10 | BS_Z0AVVB1V | pilocytic astrocytoma | — | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |